我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

药物溶栓治疗急性心肌梗死的进展(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2003年第5期
页码:
461-463,466
栏目:
综述
出版日期:
2003-09-01

文章信息/Info

Title:
-
作者:
王海明 综述; 孙晓斐 审校
济宁市第一人民医院, 山东 济宁272011
Author(s):
-
关键词:
心肌梗塞; 急性; 药物溶栓
Keywords:
-
分类号:
R542.22
DOI:
-
文献标识码:
A
摘要:
本文对急性心肌梗死药物溶栓及抗栓的治疗进展进行综述,旨在进一步提高溶栓疗效、减少不良反应。
Abstract:
-

参考文献/References

[1] 链激酶加速溶栓试验协作组. 急性心肌梗死患者链激酶加速溶栓疗法的多中心临床试验 [J] . 中华心血管病杂志, 2000, 28(3):192-196.

[2] 中华医学会心血管病学分会等. 急性心肌梗死诊断和治疗指南 [J] . 中华心血管病杂志, 2001, 29(12):713-714.

[3] 重组组织型纤溶酶原激活剂与尿激酶对比研究组。国人小剂量重组组织型纤溶酶原激活剂与尿激酶治疗急性心肌梗塞随机对照研究 [J] . 中华心血管病杂志, 1999, 27(3):174.

[4] 李亚平. 急性心肌梗死的药物溶栓治疗进展 [J] . 实用老年医学, 2000, 14(2):86.

[5] 周红. 第三代溶栓剂的作用特点及其研究现状 [J] .国外医学*心血管疾病分册, 2000, 27(5):275.

[6] Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombiant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase inpatients with acute myocardial infarction: Results of the HIT-4 trial [J] . J Am Coll Cardiol, 1999, 34:966-973.

[7] Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial [J] . Circulation, 1999, 99:2720-2732.

[8] The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with ibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTOV randomised trial [J] . Lancet, 2001, 357:1905.

[9] Newby LK. Long-term or alplatelet glycoproteinⅡ b/Ⅲ a receptor antagonism with sibrafiban after acute coronary syndromes: study design of the Sibrafiban vs aspirinto Yield Maximum Protection from ischemic Heart events post acute coronary syndromes (SYMPHONY) trial [J] . Am Heart J, 1999, 138:210-218.

[10] The SYMPHONY investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomized trial [J] . Lancet, 2000, 355:337-345.

[11] Fostfeldt G, Ahlberg G, Gustafsson G, et al. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--apilot study: biochemical markers in acute coronary syndromes (BIOMACS II) [J] . J Am Coll Cardiol, 1999, 33(3):627-633.

[12] Wllentin L, Dellborg DM, Lindahl B, et al. The low molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study [J] . Clin Cardiol, 2001, 24(3,Suppl):I12-I14.

[13] Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive tore combinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II) [J] . Circulation, 2001, 104(6):648-652.

[14] Hobbach HP, Schuster P. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction [J] . Lancet, 2001, 358(9282):605-613.

备注/Memo

备注/Memo:
收稿日期：2002-10-03.
更新日期/Last Update: 2003-09-01